← All trials
NCT04626414
Phase 1Interventional
Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Sep 28, 2020
- Primary completion
- Nov 15, 2020
- Completion date
- Nov 15, 2020
- First posted
- Nov 12, 2020
- Last posted
- Nov 12, 2020
- Enrollment
- 32
- Arms / groups
- 4 / —
- Source
- AACT · ingestion pipeline
Sponsors
- Shield TherapeuticsLead sponsor
- Shield TherapeuticsStudy director
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.